Philip Lab Publications

Budde Lihua E.,  Wu David,  Martin Daniel B.,  Philip Mary,  Shustov Andrei R.,  Smith Stephen D., Gooley Ted A., Chen   Tara L., Libby Edward N., Chen Eric Y.,  Kojouri Kiarash, Langerak Alan, Roden Jennifer E., Press  Oliver W., Gopal  Ajay K., Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol. 2018 Full text

Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, Scott AC, Viale A, Lauer P, Merghoub T, Hellmann MD, Wolchok JD, Leslie CS, Schietinger A. Chromatin states define tumour-specific T cell dysfunction and reprogrammingNature [print-electronic]. 2017 May 5/25/2017; 545(7655): 452-6. PMID: 28514453, PII: nature22367, DOI: 10.1038/nature22367, ISSN: 1476-4687. 

Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, Schell TD, Garbi N, Greenberg PD. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during TumorigenesisImmunity [print-electronic]. 2016 Aug 8/16/2016; 45(2): 389-401. PMID: 27521269, PMCID: PMC5119632, PII: S1074-7613(16)30284-9, DOI: 10.1016/j.immuni.2016.07.011, ISSN: 1097-4180. 

Cowan AJ, Stevenson PA, Cassaday RD, Graf SA, Fromm JR, Wu D, Holmberg LA, Till BG, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR, Green DJ, Libby EN, Bensinger WI, Shadman M, Maloney DG, Press OW, Gopal AK. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete RemissionBiol. Blood Marrow Transplant [print-electronic]. 2016 Feb; 22(2): 380-5. PMID: 26348890, PMCID: PMC4716882, PII: S1083-8791(15)00596-0, DOI: 10.1016/j.bbmt.2015.08.035, ISSN: 1523-6536. 

Philip M, Chiu EY, Hajjar AM, Abkowitz JL. TLR Stimulation Dynamically Regulates Heme and Iron Export Gene Expression in MacrophagesJ Immunol Res [print-electronic]. 2016; 2016: 4039038. PMID: 27006955, PMCID: PMC4783552, DOI: 10.1155/2016/4039038, ISSN: 2314-7156. 

Cassaday RD, Stevenson PA, Gooley TA, Chauncey TR, Pagel JM, Rajendran J, Till BG, Philip M, Orozco JJ, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Smith SD, Libby EN, Maloney DG, Press OW, Gopal AK. High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphomaBr. J. Haematol [print-electronic]. 2015 Dec; 171(5): 788-97. PMID: 26455717, PMCID: PMC4715476, DOI: 10.1111/bjh.13773, ISSN: 1365-2141. 

Onishi M, Graf SA, Holmberg L, Behnia S, Shustov AR, Schiavo K, Philip M, Libby EN, Cassaday RD, Pagel JM, Roden JE, Maloney DG, Green DJ, Till BG, Press OW, Smith SD, Gopal AK. Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative statusHematol Oncol [print-electronic]. 2015 Dec; 33(4): 187-91. PMID: 25236531, PMCID: PMC4366342, DOI: 10.1002/hon.2166, ISSN: 1099-1069. 

Philip M, Schietinger A. Beyond Genomics: Multidimensional Analysis of Cancer Therapy ResistanceTrends Immunol [print-electronic]. 2015 Nov; 36(11): 665-7. PMID: 26440701, PMCID: PMC5104493, PII: S1471-4906(15)00220-3, DOI: 10.1016/, ISSN: 1471-4981. 

Graf SA, Stevenson PA, Holmberg LA, Till BG, Press OW, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR, Green DJ, Libby EN, Bensinger WI, Pagel JM, Maloney DG, Zhou Y, Cassaday RD, Gopal AK. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphomaAnn. Oncol [print-electronic]. 2015 Nov; 26(11): 2323-8. PMID: 26347113, PMCID: PMC4621031, PII: mdv364, DOI: 10.1093/annonc/mdv364, ISSN: 1569-8041. 

Philip M, Funkhouser SA, Chiu EY, Phelps SR, Delrow JJ, Cox J, Fink PJ, Abkowitz JL. Heme exporter FLVCR is required for T cell development and peripheral survivalJ. Immunol [print-electronic]. 2015 Feb 2/15/2015; 194(4): 1677-85. PMID: 25582857, PMCID: PMC4323866, PII: jimmunol.1402172, DOI: 10.4049/jimmunol.1402172, ISSN: 1550-6606. 

Phipps C, Gopal AK, Storer BE, Cassaday RD, Press OW, Till BG, Pagel JM, Palanca-Wessels MC, Philip M, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Chauncey T, Maloney DG, Libby EN. Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivityLeuk. Lymphoma [print-electronic]. 2015 Jan; 56(1): 92-6. PMID: 24707941, PMCID: PMC4269586, DOI: 10.3109/10428194.2014.911866, ISSN: 1029-2403. 

Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Palanca-Wessels MC, Philip M, Bensinger WI, Holmberg LA, Shustov A, Green DJ, Libby EN, Maloney DG, Gopal AK. Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantationBiol. Blood Marrow Transplant [print-electronic]. 2013 Sep; 19(9): 1403-6. PMID: 23871782, PMCID: PMC3788600, PII: S1083-8791(13)00299-1, DOI: 10.1016/j.bbmt.2013.07.005, ISSN: 1523-6536. 

Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H. Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phaseJ. Exp. Med [print-electronic]. 2010 Oct 10/25/2010; 207(11): 2469-77. PMID: 20921286, PMCID: PMC2964573, PII: jem.20092450, DOI: 10.1084/jem.20092450, ISSN: 1540-9538. 

Philip M, Schietinger A, Schreiber H. Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cellsImmunology [print-electronic]. 2010 Aug; 130(4): 494-503. PMID: 20331471, PMCID: PMC2913260, PII: IMM3258, DOI: 10.1111/j.1365-2567.2010.03258.x, ISSN: 1365-2567. 

Schietinger A, Philip M, Schreiber H. Specificity in cancer immunotherapySemin. Immunol [print-electronic]. 2008 Oct; 20(5): 276-85. PMID: 18684640, PMCID: PMC3644553, PII: S1044-5323(08)00054-7, DOI: 10.1016/j.smim.2008.07.001, ISSN: 1044-5323. 

Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, Schreiber H. A mutant chaperone converts a wild-type protein into a tumor-specific antigenScience. 2006 Oct 10/13/2006; 314(5797): 304-8. PMID: 17038624, PII: 314/5797/304, DOI: 10.1126/science.1129200, ISSN: 1095-9203. 

Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer inductionSemin. Cancer Biol. 2004 Dec; 14(6): 433-9. PMID: 15489136, PII: S1044579X04000495, DOI: 10.1016/j.semcancer.2004.06.006, ISSN: 1044-579X. 

Wu TH, Pabin CN, Qin Z, Blankenstein T, Philip M, Dignam J, Schreiber K, Schreiber H. Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18J. Immunol. 2004 Mar 3/1/2004; 172(5): 3243-51. PMID: 14978132, ISSN: 0022-1767. 

Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu YX. Priming of naive T cells inside tumors leads to eradication of established tumorsNat. Immunol [print-electronic]. 2004 Feb; 5(2): 141-9. PMID: 14704792, PII: ni1029, DOI: 10.1038/ni1029, ISSN: 1529-2908. 

Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gammaProc. Natl. Acad. Sci. U.S.A. 1999 Jul 7/20/1999; 96(15): 8633-8. PMID: 10411927, PMCID: PMC17568, ISSN: 0027-8424.